How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Diagnosis of osteoarthritis - Thrombospondin-4 autoantibodies for the diagnosis of osteoarthritis

Organization name

PROvendis GmbH

Profile

Osteoarthritis (OA) is the most common degenerative disease of joints world-wide. About two-third of people over 65 years are affected, whereas the etiology is largely unclear. Currently, there is no causative therapy avaible, which is due to the complex pathomechanisms of arthrosis and also due to the lack of diagnostic biomarkers that allow monitoring of therapeutic success of drug candidates.

Researchers of the University of Cologne have found that autoantibodies against the cartilage protein thrombospondin 4 (TSP-4) occur in the course of arthrosis. Rheumatoid arthritis is characterized by the presence of autoantibodies, but autoantibodies against TSP-4 have jet not been described for arthrosis.

In addition to TSP-4, the researchers have found autoantibodies against the cartilage oligomeric matrix protein (COMP) and the C-type lectin domain family 3 member A (CLEC3A) in the course of OA, which may be used in a combined test together with TSP-4 in order to strengthen significance of diagnosis (Table 1).

The present invention is the first serum biomarker test that helps to support the clinical diagnosis of OA and furthermore may provide a tool that allows the monitoring of therapeutic success of drug candidates for the treatment of arthrosis.

Competitive Advantages

  • First biomarker of osteoarthritis

Commercial Opportunities

The invention is offered for licensing and further development as diagnostic test.

Current Status

In case of interest we are pleased to inform you about the patent status.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries